GNOM
Global X Genomics & Biotechnology ETF
The Global X Genomics & Biotechnology ETF seeks to invest in companies that potentially stand to benefit from further advances in the field of genomic science.
Global
EQUITY
Rules-Based
MANAGEMENT STYLE
$ 54.0 M
ASSETS UNDER MGMT
50 bp
EXPENSES
Fund Basics
| Inception date | Apr 05, 2019 |
| Regulation | Open-Ended Fund |
| Fund Website | link... |
| Distributions | Quarterly |
| Currency | USD |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | Yes |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
Complete list +
| GUARDANT HEALTH, INC. | 5.6 % |
| ILLUMINA INC | 4.8 % |
| NATERA INC | 4.2 % |
| BIOMARIN PHARMACEUTICAL INC | 4.1 % |
| ARROWHEAD PHARMACEUTICALS, INC. | 4.1 % |
| LEGEND BIOTECH CORPORATION SPONSORED ADR | 4.1 % |
| PRAXIS PRECISION MEDICINES, INC. | 4.0 % |
| TWIST BIOSCIENCE CORP. | 4.0 % |
| VERTEX PHARMACEUTICALS INC | 4.0 % |
| CRISPR THERAPEUTICS AG | 3.9 % |
Constituent Breakdown
| Number of holdings | 50 |
| Herfindahl-Hirschman Index | 312 |
| Wgt avg mkt cap (mns) | $50,953 |
| Large cap (>$10bn) | 46.1% |
| Mid cap ($2-10bn) | 41.6% |
| Small cap (<$2bn) | 12.4% |
| Developed mkts. | 95.9% |
| Emerging mkts. | 2.3% |
Sector Breakdown
Country Exposure
 |
UNITED STATES | 82.8 % |
 |
NETHERLANDS | 5.1 % |
 |
SWITZERLAND | 3.9 % |
 |
GERMANY | 3.4 % |
 |
CHINA | 1.9 % |
 |
BRITAIN | 1.8 % |
 |
SINGAPORE | 1.0 % |
Historical Performance
Standardized Performance (as of 05/31/2026)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | 9.3% | 59.9% | 10.6% | 0.5% | -10.4% | -- | -- | -2.9% |
| Dividend Yield | 0.0% | 2.2% | 0.8% | 0.5% | 0.3% | -- | -- | 0.2% |
| Total Returns | 9.3% | 62.1% | 11.4% | 1.0% | -10.1% | -- | -- | -2.7% | Ann. Volatility | 28.8% | 26.5% | 30.0% | 29.5% | 33.6% | -- | -- | 226.1% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 1.32 | 34% |
| MSCI EAFE | 1.03 | 34% |
| MSCI Emg Mkts | 0.67 | 25% |
Liquidity Measures
| Avg. volume (000) | 11 |
| ADV traded (mns) | $1 |
| Turnover | 1.0% |
| Avg. Bid/Ask (% of price) | 0.50% |
Technical Indicators
| 30d moving avg. (EMA) | $46.30 |
| Relative strength (RSI) | 60 |
| MACD/Signal | 0.74/0.31 |
| Bollinger Bands (Upper/Lower) | $49.27/$43.39 |
| Short interest (% of AUM) | 0.2% |
Distributions
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. GNOM |
Expenses vs. GNOM |
ALTAR Score™ vs. GNOM |
|---|---|---|---|---|
| GNMX | Corgi Genomics & Precision Medicine ETF | 43.5% | -15 bp | -1.2% |
| ARKG | ARK Genomic Revolution ETF | 37.9% | +25 bp | +1.6% |
| WDNA | WisdomTree BioRevolution Fund | 32.5% | -5 bp | +0.1% |
| FBT | First Trust NYSE Arca Biotechnology Index Fund | 31.0% | +6 bp | +5.0% |
| HELX | Franklin Genomic Advancements ETF | 28.7% | 0 bp | +2.1% |
| EKG | First Trust Nasdaq Lux Digital Health Solutions ETF | 23.2% | +15 bp | +4.2% |
| BBH | VanEck Biotech ETF | 22.4% | -15 bp | +7.9% |
| HTEC | ROBO Global Healthcare Technology and Innovation ETF | 21.2% | +18 bp | +5.5% |
| PBE | Invesco Biotechnology & Genome ETF | 21.0% | +8 bp | +6.2% |
| IBB | iShares Biotechnology ETF | 19.7% | -5 bp | +2.5% |
Risk and Returns: GNOM vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (USD)
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Book value per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 6/3/2026
Peer Group Comparison
Sample data. Subscribe for access.
Historical Valuation Trends Sample data. Subscribe for access.
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
-3.1%
ALTAR SCORE™
1st
PERCENTILE
AVOID
ETFRC RATING
There are 727 funds in the Global Equity category with an average
ALTAR Score™ of 4.3% and a standard deviation
of 2.6%. GNOM's ALTAR Score™ is approximately -2.8 standard
deviations above the category average. This places GNOM in the 1st percentile
among funds in the category.
Sell-Side Consensus
$62.79
PRICE TARGET
+30.7%
UPSIDE